Wikipedia -WSS

Wikipedia

author：fashion 2025-09-27 13:04:28 - browse：52195

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： More doctors should go into startup world

entertainment

WSS

White House calls on federal agencies to crack down on AI abuses

23andMe had bad news about my health. I wish a person had delivered it

Removing probiotics from the NICU could threaten preemies' health

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

In age of alternative facts, a scholarly course on calling out crap

The Sacklers, horror, and ‘The Fall of the House of Usher’

focus

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Wildfire smoke exposes gaps in outdoor worker protections

What does generative AI mean for health care? We asked experts

Walensky prepares to leave CDC — and Congress — behind

The high cost of giving birth even with insurance

Medicare proposal to cover medical devices draws a mixed reaction

How one medical school became remarkably diverse

Psychedelics group wrestles with new pharma identity

The cancer drug shortage isn’t new — and neither are the solutions

DIEP, the 'gold standard' of breast reconstruction, is under threat

More doctors should go into startup world

knowledge

Walensky prepares to leave CDC — and Congress — behind

New air purifier tech could be key to improving indoor air quality

Trump demands the U.S. pay no more for drugs than other countries … again

Duchenne breakthrough therapy leaves behind pioneering families

Just how powerful is the placebo effect?

Cancer drug shortages should be causing more outrage

hotspot

knowledge

entertainment

Wikipedia